Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study

PURPOSE: Patients with pancreatic cancer often have cancer cachexia at diagnosis. Recent studies suggested that loss of skeletal muscle mass was related to cancer cachexia, which hindered continuance of chemotherapy and could be one of prognostic factors in pancreatic cancer, however the association...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yukari, Saito, Kei, Nakai, Yousuke, Oyama, Hiroki, Kanai, Sachiko, Suzuki, Tatsunori, Sato, Tatsuya, Hakuta, Ryunosuke, Ishigaki, Kazunaga, Saito, Tomotaka, Hamada, Tsuyoshi, Takahara, Naminatsu, Tateishi, Ryosuke, Fujishiro, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981495/
https://www.ncbi.nlm.nih.gov/pubmed/36862196
http://dx.doi.org/10.1007/s00520-023-07659-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981495/
https://www.ncbi.nlm.nih.gov/pubmed/36862196
http://dx.doi.org/10.1007/s00520-023-07659-w

Ejemplares similares